OBJECTIVE: The objective of this study was to evaluate peri-operative and survival outcomes of ovarian cancer patients undergoing percutaneous upper gastrointestinal decompression for malignant bowel obstruction (MBO). METHODS: Retrospective chart review was used to identify patients with ovarian, peritoneal, or fallopian tube cancer who underwent palliative decompressive treatment for MBO from 1/2002 to 12/2010. Kaplan-Meier methods were used to estimate the median survival (MS) and multivariate analysis used to determine if any variables were associated with the hazard of death. RESULTS: Fifty-three patients met inclusion criteria. Median length of diagnosis prior to intervention was 21 months. Fifteen (28.3%) patients experienced complications and 9 required revision. Forty-nine (92.5%) experienced relief of symptoms after placement, and 91% tolerated some form of oral intake. Following placement, 19 (36%) patients received additional chemotherapy and 21(41%) patients received total parental nutrition (TPN). Thirty-five patients were discharged home/outpatient facility, 16 to hospice care, and 2 died prior to discharge. MS for all patients was 46 days. Patients who received chemotherapy had a MS of 169 days compared to 33 days (p<0.001). We failed to find an association between survival and TPN or performance status. CONCLUSIONS: Malignant bowel obstruction is a common complication of ovarian cancer. Management is palliative; risks and benefits of any therapy must be considered. Percutaneous decompressive therapy provides relief from associated symptoms, and allows patients to be discharged home. Median survival in this group is limited, and decisions regarding aggressive therapy should be individualized.
OBJECTIVE: The objective of this study was to evaluate peri-operative and survival outcomes of ovarian cancerpatients undergoing percutaneous upper gastrointestinal decompression for malignant bowel obstruction (MBO). METHODS: Retrospective chart review was used to identify patients with ovarian, peritoneal, or fallopian tube cancer who underwent palliative decompressive treatment for MBO from 1/2002 to 12/2010. Kaplan-Meier methods were used to estimate the median survival (MS) and multivariate analysis used to determine if any variables were associated with the hazard of death. RESULTS: Fifty-three patients met inclusion criteria. Median length of diagnosis prior to intervention was 21 months. Fifteen (28.3%) patients experienced complications and 9 required revision. Forty-nine (92.5%) experienced relief of symptoms after placement, and 91% tolerated some form of oral intake. Following placement, 19 (36%) patients received additional chemotherapy and 21(41%) patients received total parental nutrition (TPN). Thirty-five patients were discharged home/outpatient facility, 16 to hospice care, and 2 died prior to discharge. MS for all patients was 46 days. Patients who received chemotherapy had a MS of 169 days compared to 33 days (p<0.001). We failed to find an association between survival and TPN or performance status. CONCLUSIONS:Malignant bowel obstruction is a common complication of ovarian cancer. Management is palliative; risks and benefits of any therapy must be considered. Percutaneous decompressive therapy provides relief from associated symptoms, and allows patients to be discharged home. Median survival in this group is limited, and decisions regarding aggressive therapy should be individualized.
Authors: E Campagnutta; R Cannizzaro; A Gallo; A Zarrelli; M Valentini; M De Cicco; C Scarabelli Journal: Gynecol Oncol Date: 1996-07 Impact factor: 5.482
Authors: Laurent Brard; Sherry Weitzen; Suzanne L Strubel-Lagan; Narasimha Swamy; Mary E Gordinier; Richard G Moore; Cornelius O Granai Journal: Gynecol Oncol Date: 2006-03-27 Impact factor: 5.482
Authors: D F Kolomainen; A Daponte; D P J Barton; K Pennert; T E J Ind; J E Bridges; J H Shepherd; M E Gore; S B Kaye; J Riley Journal: Gynecol Oncol Date: 2011-11-12 Impact factor: 5.482
Authors: Anne M Silas; Lindsay F Pearce; Lisa S Lestina; Margaret R Grove; Anna Tosteson; Wendy D Manganiello; Michael A Bettmann; Stuart R Gordon Journal: Eur J Radiol Date: 2005-10 Impact factor: 3.528
Authors: Kimberly Moore Dalal; Marc J Gollub; Thomas J Miner; W Douglas Wong; Hans Gerdes; Mark A Schattner; David P Jaques; Larissa K F Temple Journal: J Palliat Med Date: 2011-05-19 Impact factor: 2.947
Authors: Dennis S Chi; Rebecca Phaëton; Thomas J Miner; Steven V Kardos; John P Diaz; Mario M Leitao; Ginger Gardner; Jae Huh; William P Tew; Jason A Konner; Yukio Sonoda; Nadeem R Abu-Rustum; Richard R Barakat; David P Jaques Journal: Oncologist Date: 2009-08-14
Authors: Anne Dittrich; Barbara Schubert; Michael Kramer; Felicitas Lenz; Karin Kast; Ulrich Schuler; Markus K Schuler Journal: Support Care Cancer Date: 2017-04-22 Impact factor: 3.603
Authors: Rudy S Suidan; Weiguo He; Charlotte C Sun; Hui Zhao; Lois M Ramondetta; Brian D Badgwell; Diane C Bodurka; Karen H Lu; Sharon H Giordano; Larissa A Meyer Journal: Int J Gynecol Cancer Date: 2017-09 Impact factor: 3.437
Authors: Yeh Chen Lee; Nazlin Jivraj; Catherine O'Brien; Tanya Chawla; Eran Shlomovitz; Sarah Buchanan; Jenny Lau; Jennifer Croke; Johane P Allard; Preeti Dhar; Stephane Laframboise; Sarah E Ferguson; Neesha Dhani; Marcus Butler; Pamela Ng; Terri Stuart-McEwan; Pamela Savage; Lisa Tinker; Amit M Oza; Stephanie Lheureux Journal: Obstet Gynecol Int Date: 2018-05-17
Authors: Robert D Morgan; Sofia Stamatopoulou; Nerissa Mescallado; Geoff Saunders; Richard Welch; Claire Mitchell; Jurjees Hasan; Andrew R Clamp; Gordon C Jayson Journal: ESMO Open Date: 2019-03-21
Authors: Ainhoa Madariaga; Jenny Lau; Arunangshu Ghoshal; Tomasz Dzierżanowski; Philip Larkin; Jacek Sobocki; Andrew Dickman; Kate Furness; Rouhi Fazelzad; Gregory B Crawford; Stephanie Lheureux Journal: Support Care Cancer Date: 2022-03-10 Impact factor: 3.359